Empowering Patients and Care Partners Read more about Empowering Patients and Care PartnersAdd new comment
IMF Chief Medical Officer Dr. Joseph Mikhael Interviewed About Disparities in Myeloma Clinical Trials Read more about IMF Chief Medical Officer Dr. Joseph Mikhael Interviewed About Disparities in Myeloma Clinical TrialsAdd new comment
IMF Chief Medical Officer Dr. Joseph Mikhael Comments on Collaboration to Address Disparities in Myeloma Care Read more about IMF Chief Medical Officer Dr. Joseph Mikhael Comments on Collaboration to Address Disparities in Myeloma Care Add new comment
The International Myeloma Foundation (IMF) Amplifies #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2023 Read more about The International Myeloma Foundation (IMF) Amplifies #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2023 Add new comment
NLB Symposium at the 2023 ONS Congress Read more about NLB Symposium at the 2023 ONS CongressAdd new comment
European Commission Grants Conditional Marketing Authorization of TALVEY® (talquetamab) for Some Patients with Relapsed/Refractory Myeloma Read more about European Commission Grants Conditional Marketing Authorization of TALVEY® (talquetamab) for Some Patients with Relapsed/Refractory MyelomaAdd new comment
The International Myeloma Foundation (IMF) Welcomes Visionary & Strategic Fundraiser Sylvia Dsouza as Vice President of Philanthropy Read more about The International Myeloma Foundation (IMF) Welcomes Visionary & Strategic Fundraiser Sylvia Dsouza as Vice President of Philanthropy Add new comment
IMF Honors Two Outstanding Researchers: Dr. María-Victoria Mateos and Dr. Thomas Martin Read more about IMF Honors Two Outstanding Researchers: Dr. María-Victoria Mateos and Dr. Thomas MartinAdd new comment
FDA Grants Accelerated Approval for ELREXFIO™ (elranatamab-bcmm) for Heavily Pre-treated Multiple Myeloma Patients Read more about FDA Grants Accelerated Approval for ELREXFIO™ (elranatamab-bcmm) for Heavily Pre-treated Multiple Myeloma PatientsAdd new comment
FDA Approves TALVEY™ (talquetamab-tgvs) for Heavily Pre-Treated Multiple Myeloma Read more about FDA Approves TALVEY™ (talquetamab-tgvs) for Heavily Pre-Treated Multiple MyelomaAdd new comment
